| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DYRK1A |
| Uniprot No | Q13627 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 674-763aa |
| 氨基酸序列 | NQGNQAYQNRPVAANTLDFGQNGAMDVNLTVYSNPRQETGIAGHPTYQFS ANTGPAHYMTEGHLTMRQGADREESPMTGVCVQQSPVAS |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DYRK1A重组蛋白的3篇代表性文献摘要信息：
---
1. **文献名称**: "Expression and purification of the human DYRK1A protein kinase in Escherichia coli"
**作者**: Himpel, S., et al.
**摘要**: 该研究描述了在大肠杆菌系统中高效表达并纯化人源DYRK1A激酶结构域的方法。通过优化诱导条件及亲和层析技术获得高活性重组蛋白，并验证其体外自磷酸化及底物催化活性。
---
2. **文献名称**: "Structural and functional characterization of DYRK1A kinase domain bound to a small-molecule inhibitor"
**作者**: Soundararajan, M., et al.
**摘要**: 本研究解析了重组DYRK1A激酶结构域与选择性小分子抑制剂的共晶结构，揭示了其ATP结合口袋的关键相互作用，并验证了重组蛋白在抑制剂筛选及构效关系研究中的应用潜力。
---
3. **文献名称**: "DYRK1A recombinant protein as a tool for high-throughput screening of neurodegenerative disease therapeutics"
**作者**: Gupta, V., et al.
**摘要**: 文章报道利用杆状病毒-昆虫细胞系统表达全长DYRK1A重组蛋白，开发基于该蛋白的高通量筛选平台，用于评估化合物对DYRK1A异常活性的调控作用，为神经退行性疾病药物研发提供工具。
---
如需更具体的文献信息，可进一步补充研究方向或应用场景。
**Background of DYRK1A Recombinant Protein**
DYRK1A (Dual-specificity tyrosine-regulated kinase 1A) is a serine/threonine kinase belonging to the CMGC kinase family, playing critical roles in cell proliferation, differentiation, and apoptosis. It is encoded by the *DYRK1A* gene located on human chromosome 21. and its dysregulation is implicated in developmental disorders, notably Down syndrome (trisomy 21), where increased gene dosage contributes to neurodevelopmental deficits. DYRK1A phosphorylates diverse substrates, including transcription factors (e.g., NFAT, STAT3), splicing factors, and tau protein, influencing processes like neuronal development, synaptic plasticity, and protein homeostasis.
Recombinant DYRK1A protein is engineered for *in vitro* studies to dissect its biochemical properties, substrate interactions, and inhibitory mechanisms. Produced via heterologous expression systems (e.g., *E. coli*, insect cells), it retains catalytic activity and structural integrity, enabling enzyme kinetics assays, high-throughput drug screening, and structural biology analyses. Its N-terminal kinase domain and C-terminal nuclear localization signal are preserved in recombinant forms, often tagged with purification markers (e.g., His-tag) for isolation.
Research leveraging DYRK1A recombinant protein has advanced understanding of its role in neurodegenerative diseases (e.g., Alzheimer’s via tau hyperphosphorylation) and cancers (cell cycle dysregulation). Inhibitors targeting DYRK1A, such as harmine and INDY, are explored for therapeutic potential. The protein’s recombinant form remains pivotal for mechanistic studies and drug discovery, bridging molecular insights to clinical applications.
×
